Celldex/$CLDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Celldex
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Ticker
$CLDX
Sector
Primary listing
Employees
186
Headquarters
Website
Celldex Metrics
BasicAdvanced
$1.8B
-
-$3.01
1.33
-
Price and volume
Market cap
$1.8B
Beta
1.33
52-week high
$29.05
52-week low
$14.40
Average daily volume
1M
Financial strength
Current ratio
19.671
Quick ratio
19.125
Long term debt to equity
0.228
Total debt to equity
0.462
Profitability
EBITDA (TTM)
-231.405
Gross margin (TTM)
-3,337.17%
Net profit margin (TTM)
-3,447.48%
Operating margin (TTM)
-4,054.40%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-19.08%
Return on equity (TTM)
-27.17%
Valuation
Price to revenue (TTM)
306.275
Price to book
2.71
Price to tangible book (TTM)
2.88
Price to free cash flow (TTM)
-9.408
Free cash flow yield (TTM)
-10.63%
Free cash flow per share (TTM)
-2.84
Growth
Revenue change (TTM)
-30.27%
Earnings per share change (TTM)
12.24%
3-year revenue growth (CAGR)
91.61%
10-year revenue growth (CAGR)
1.00%
3-year earnings per share growth (CAGR)
11.91%
10-year earnings per share growth (CAGR)
-17.20%
What the Analysts think about Celldex
Analyst ratings (Buy, Hold, Sell) for Celldex stock.
Bulls say / Bears say
Data from the Phase 2 barzolvolimab study in chronic spontaneous urticaria showed that 41% of patients maintained a complete response seven months post-dosing and 48% reported no impact on quality of life, with a favorable safety profile, supporting ongoing Phase 3 enrollment (Nasdaq[turn1search1]).
As of June 30, 2025, cash, cash equivalents and marketable securities totaled $630.3 million, providing a runway to fund operations through at least 2027 and underlining the company’s financial resilience despite clinical investment (Globe Newswire[turn9search0]).
The pipeline has progressed with global Phase 3 trials underway for barzolvolimab in CSU, a Phase 3 program in chronic inducible urticaria under development, enrollment complete in Phase 2 EoE, and an active Phase 1 trial of CDX-622, demonstrating diversified clinical momentum (Globe Newswire[turn4search1]).
Q2 2025 net loss widened to $56.6 million (−$0.85 per share) versus $35.8 million (−$0.54 per share) in Q2 2024, reflecting a 57.9% year-over-year increase in R&D-driven losses (Nasdaq[turn9search0]).
Total revenue in Q2 2025 plummeted to just $0.7 million, a 72% decline from $2.5 million in Q2 2024, underscoring the company’s continued reliance on grants and service agreements rather than product sales (Nasdaq[turn9search0]).
Celldex warns that significant scale-up of its manufacturing processes may encounter unanticipated technical challenges and require additional FDA-approved validation studies, posing risks to supply continuity and commercialization timelines (SEC 10-Q[turn9search7]).
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.
Celldex Financial Performance
Revenues and expenses
Celldex Earnings Performance
Company profitability
Celldex News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Celldex stock?
Celldex (CLDX) has a market cap of $1.8B as of October 24, 2025.
What is the P/E ratio for Celldex stock?
The price to earnings (P/E) ratio for Celldex (CLDX) stock is 0 as of October 24, 2025.
Does Celldex stock pay dividends?
No, Celldex (CLDX) stock does not pay dividends to its shareholders as of October 24, 2025.
When is the next Celldex dividend payment date?
Celldex (CLDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Celldex?
Celldex (CLDX) has a beta rating of 1.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.